Mimicking dominant negative inhibition of prion replication through structure-based drug design

Véronique Perrier, Andrew C. Wallace, Kiyotoshi Kaneko, Jiri Safar, Stanley B. Prusiner, Fred E. Cohen

Proceedings of the National Academy of Sciences · 2000 · 180 citations · 45 references

Concepts

TL;DR

Recent structural insights into PrP C and its auxiliary molecules enable a more rational design of therapeutics against prion replication. The study aims to discover lead compounds that emulate dominant‑negative PrP C mutants to block PrP Sc formation. Using the Available Chemicals Directory, the authors computationally screened for molecules mimicking residues 168, 172, 215, and 219 of PrP C, visually evaluated 1,000 candidates, and tested 63 in scrapie‑infected mouse neuroblastoma cells. Two compounds, Cp‑60 and Cp‑62, dose‑dependently inhibited PrP Sc formation with low toxicity, and related analogues showed similar activity, suggesting this strategy could broadly target harmful protein–protein interactions.

Abstract

Recent progress determining the structure of the host-encoded prion protein (PrP C ) and the role of auxiliary molecules in prion replication permits a more rational approach in the development of therapeutic interventions. Our objective is to identify a new class of lead compounds that mimic the dominant negative PrP C mutants, which inhibit an abnormal isoform (PrP Sc ) formation. A computational search was conducted on the Available Chemicals Directory for molecules that mimic both the spatial orientation and basic polymorphism of PrP residues 168, 172, 215, and 219, which confer dominant negative inhibition. The search revealed 1,000 potential candidates that were visually analyzed with respect to the structure of this four-residue epitope on PrP C . Sixty-three compounds were tested for inhibition of PrP Sc formation in scrapie-infected mouse neuroblastoma cells (ScN2a). Two compounds, Cp-60 (2-amino-6-[(2-aminophenyl)thio]-4-(2-furyl)pyridine-3,5-dicarbonitrile) and Cp-62 ( N ′1-({5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-2-furyl}carbonyl)-4 methoxybenzene-1-sulfonohydrazide), inhibited PrP Sc formation in a dose-dependent manner and demonstrated low levels of toxicity. A substructure search of the Available Chemicals Directory based on Cp-60 identified five related molecules, three of which exhibited activities comparable to Cp-60. Mimicking dominant negative inhibition in the design of drugs that inhibit prion replication may provide a more general approach to developing therapeutics for deleterious protein–protein interactions.

References

45